Uterine cancer is the most prevalent gynecologic tumour in women, with an estimated 40,100 cases and 6800 deaths in the United States in 2003 ([Jemal *et al*, 2003](#bib9){ref-type="other"}). On the basis of clinical and histopathologic variables, two subtypes of endometrial carcinoma, namely Type I and Type II tumours, have been described ([Bohkman, 1983](#bib1){ref-type="other"}). Type I endometrial cancers, which account for the majority (i.e., about 80%) of cases, are usually well differentiated and endometrioid in histology. These neoplasms are frequently diagnosed in younger women, are associated with a history of hyperestrogenism as the main risk factor, and typically have a favourable prognosis with appropriate therapy. Type II endometrial cancers are poorly differentiated tumours, often with serous papillary or clear cell histology, and are not associated with hyperestrogenic factors. Although Type II tumours account for only a minority of endometrial carcinoma, about 50% of all relapses occur in this group of patients.

High-throughput technologies for assaying gene expression, such as high-density oligonucleotide and cDNA microarrays, have recently been used in an attempt to define the genetic fingerprints of a variety of human tumours including endometrial cancers ([Smid-Koopman *et al*, 2000](#bib30){ref-type="other"}; [Matsushima-Nishiu *et al*, 2001](#bib16){ref-type="other"}; [Moreno-Bueno *et al*, 2003](#bib21){ref-type="other"}; [Risinger *et al*, 2003](#bib24){ref-type="other"}). These techniques may allow precise and accurate grouping of human tumours and have the potential to identify patients who are unlikely to be cured by conventional therapy ([Sorlie *et al*, 2001](#bib31){ref-type="other"}; [Rosenwald *et al*, 2002](#bib25){ref-type="other"}; [Moreno-Bueno *et al*, 2003](#bib21){ref-type="other"}; [Risinger *et al*, 2003](#bib24){ref-type="other"}). Consistent with this view, clinically relevant genes highly differentially expressed between Type I and Type II endometrial tumours have recently been identified ([Moreno-Bueno *et al*, 2003](#bib21){ref-type="other"}; [Risinger *et al*, 2003](#bib24){ref-type="other"}). Most of the differentially expressed genes in Type I tumours included genes known to be hormonally regulated during the menstrual cycle and known to be important in endometrial homeostasis (i.e., *MGB2*, *LTF*, *END1*, and *MMP11*) ([Moreno-Bueno *et al*, 2003](#bib21){ref-type="other"}; [Risinger *et al*, 2003](#bib24){ref-type="other"}). In contrast, Type II tumours have been shown to overexpress genes involved in the regulation of the mitotic spindle checkpoint and associated with aneuploidy and an aggressive phenotype, such as *STK15*, *BUB1*, and *CCNB2* ([Moreno-Bueno *et al*, 2003](#bib21){ref-type="other"}; [Risinger *et al*, 2003](#bib24){ref-type="other"}).

Uterine serous papillary tumors (USPC) represent the most aggressive variant of Type II endometrial cancer and may constitute up to 10% of endometrial tumours. The microscopic criteria for diagnosis of USPC were first outlined by [Hendrickson *et al* (1982)](#bib7){ref-type="other"}. Pleomorphism, grade III nuclear atypia with prominent nucleoli and vesicular chromatin pattern, as well as a high mitotic activity are commonly detected in this tumour. Clinically, USPC has a propensity for early intra-abdominal and lymphatic spread even at presentation and is characterised by a highly aggressive biologic behaviour ([Hendrickson *et al*, 1982](#bib7){ref-type="other"}; [Nicklin and Copeland, 1996](#bib22){ref-type="other"}). Unlike the histologically indistinguishable high-grade serous ovarian carcinomas, USPC is a chemoresistant disease from onset, with responses to combined cisplatinum-based chemotherapy in the order of 20% and of short duration ([Nicklin and Copeland, 1996](#bib22){ref-type="other"}). The overall 5-year survival is about 30% for all stages and the recurrence rate after surgery is extremely high (50--80%). A deeper understanding of the molecular basis of the aggressive biologic behaviour of USPC as well as the development of novel, more specific and more effective treatment modalities against this variant of endometrial cancer remain a high priority.

In this study, with the goal of identifying genes with a differential pattern of expression between USPC and normal endometrial cells (NEC) and to use this knowledge for the development of novel diagnostic and therapeutic markers against this disease, we used oligonucleotide microarrays which interrogate the expression of some 10 000 known genes to analyse gene expression profiling of 10 highly purified primary USPC cultures and five primary NEC. We report a number of genes which may readily distinguish USPC from normal endometrial epithelial cells. More importantly, these results highlight the novel molecular features of USPC and provide a foundation for the development of new type-specific diagnostic and therapeutic strategies for this disease.

MATERIALS AND METHODS
=====================

Establishment of USPC and NEC primary cell lines
------------------------------------------------

A total of 15 primary cell lines (i.e., 10 USPC and five NEC) were established after sterile processing of samples from surgical biopsies collected between 1997 and 2004 at the University of Arkansas for Medical Sciences, as previously described for USPC specimens ([Santin *et al*, 2002](#bib27){ref-type="other"}) and NEC cultures ([Bongso *et al*, 1988](#bib2){ref-type="other"}). All fresh samples were obtained with appropriate consent according to IRB guidelines. Tumours were staged according to the FIGO operative staging system. A total abdominal hysterectomy with bilateral salpingo oophorectomy and bilateral pelvic lymphadenectomy was performed in all uterine carcinoma patients, while normal endometrial tissue was obtained from consenting donors undergoing surgery for benign pathology. No patient received chemotherapy or radiation before surgery. The patient characteristics are described in [Table 1](#tbl1){ref-type="table"}. Tumour cells were collected for RNA extraction at a confluence of 50--80% after a minimum of two to a maximum of 10 passages *in vitro*. The epithelial nature and the purity of USPC and NEC cultures were verified by immunohistochemical staining and flow-cytometric analysis with antibodies against cytokeratin and vimentin as described previously ([Bongso *et al*, 1988](#bib2){ref-type="other"}; [Santin *et al*, 2002](#bib27){ref-type="other"}). Only primary cultures which had at least 90% viability and contained \>99% epithelial cells were used for total RNA extraction.

RNA purification and microarray hybridization and analysis
----------------------------------------------------------

Detailed protocols for RNA purification, cDNA synthesis, cRNA preparation, and hybridization to the Affymetrix Human U95Av2 GeneChip microarray were performed according to the manufacturer\'s protocols, as reported previously ([Zhan *et al*, 2002](#bib36){ref-type="other"}).

Data processing
---------------

All data used in our analyses were derived from Affymetrix 5.0 software. GeneChip 5.0 output files are given as a signal that represents the difference between the intensities of the sequence-specific perfect match probe set and the mismatch probe set, or as a detection of present, marginal, or absent signals as determined by the GeneChip 5.0 algorithm. Gene arrays were scaled to an average signal of 1500 and then analysed independently. Signal calls were transformed by the log base 2 and each sample was normalized to give a mean of 0 and variance of 1.

Gene expression data analysis
-----------------------------

Statistical analyses of the data were performed with the software packages SPSS10.0 (SPSS, Chicago, IL) and the significance analysis of microarrays (SAM) method ([Tusher *et al*, 2001](#bib33){ref-type="other"}). Genes were selected for analysis based on detection and fold change. In each comparison, genes having 'present\' detection calls in more than half of the samples in the overexpressed gene group were retained for statistical analysis if they showed \>5-fold change between groups. Retained genes were subjected to SAM to establish a false discovery rate (FDR), then further filtered via the Wilcoxon rank sum (WRS) test at alpha=0.05. The FDR obtained from the initial SAM analysis was assumed to characterise genes found significant via WRS.

Gene cluster/treeview
---------------------

The hierarchical clustering of average-linkage method with the centred correlation metric was used ([Eisen *et al*, 1998](#bib6){ref-type="other"}). For the unsupervised hierarchical clustering, a total of 7328 probe sets were scanned across 10 USPCs and five NECs. The 7328 probe sets were derived from 12 588 by filtering out all control genes, all genes with absent detections, and genes not fulfilling the test of standard deviation greater than 0.5 (0.5 being the log base 2 of the signal). Only genes significantly expressed by both WRS and SAM analyses and whose average change in expression level was at least five-fold are shown in the Results section.

Quantitative real-time PCR (q-RT--PCR)
--------------------------------------

Quantitative real-time PCR was performed with an ABI Prism 7000 Sequence Analyzer using the manufacturer\'s recommended protocol (Applied Biosystems, Foster City, CA, USA) to validate differential expression of selected genes in samples from all 15 primary cell lines (10 USPC and five NEC). Each reaction was run in triplicate. The comparative threshold cycle (*C*~T~) method was used for the calculation of amplification fold as specified by the manufacturer. Briefly, 5 *μ*g of total RNA from each sample was reverse transcribed using SuperScript II Rnase H Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA). In all, 10 *μ*l of reverse-transcribed RNA samples (from 500 *μ*l of total volume) was amplified by using the TaqMan Universal PCR Master Mix (Applied Biosystems) to produce PCR products specific for *cyclin-dependent kinase inhibitor 2A* (*CDKN2A/p16* and *CDKN2A/p14ARF*), *L1 cell adhesion molecule* (*L1CAM*), *claudin-3*, *claudin-4*, *GRB7*, and *c-erbB2*. Primers specific for 18s ribosomal RNA and empirically determined ratios of 18s competimers (Applied Biosystems) were used to control for the amounts of cDNA generated from each sample. Sequences for primers and probes are available on request. Differences among USPC and NEC in the q-RT--PCR expression data were tested using the Kruskal--Wallis nonparametric test. Pearson product--moment correlations were used to estimate the degree of association between the microarray and q-RT--PCR data.

Claudin-4 immunostaining of formalin-fixed tumour tissues
---------------------------------------------------------

Claudin-4 protein expression was evaluated by immunohistochemical staining on formalin-fixed tumour tissue from which primary cultures were obtained. In addition, to further confirm transcriptional profiling results of USPC, claudin-4 marker was also evaluated by immunohistochemistry in a second independent set of eight USPC clinical tissue samples obtained from patients harbouring advanced stage disease (i.e., stage III and IV) treated at the UAMS during the same period. Study blocks were selected after histopathologic review by a surgical pathologist. The most representative haematoxylin and eosin-stained block sections were used for each specimen. Briefly, immunohistochemical stains were performed on 4-*μ*m-thick sections of formalin-fixed, paraffin-embedded tissue. After pretreatment with 10 m[M]{.smallcaps} citrate buffer at pH 6.0 using a steamer, they were incubated with mouse anti-claudin-4 antibodies (cat. \#: 18-7341; Zymed Laboratories Inc., San Francisco, CA, USA) at 1 : 2000 dilution. Antigen-bound primary antibodies were detected using standard avidin--biotin immunoperoxidase complex (Dako Corp., Carpinteria, CA, USA). Cases with less than 10% staining in tumour cells were considered negative for claudin expression, while positive cases were classified as follows regarding the intensity of claudin-4 protein expression: (a) +, focal membrane staining; (b) ++, diffuse membrane staining; and (c) +++, diffuse membrane and cytoplasmic staining.

*Clostridium perfringens* enterotoxin (CPE) treatment of primary USPC cell lines and trypan blue exclusion test
---------------------------------------------------------------------------------------------------------------

Tumour samples obtained from three patients harbouring advanced USPC (i.e., USPC 1, USPC 2, and USPC 3) and two NEC cultures derived from similar-aged women were seeded at a concentration of 1 × 10^5^ cells well^−1^ into six-well culture plates (Costar, Cambridge, MA, USA) with the appropriate medium. Tumour samples and control cell lines were grown to 80% confluence. After washing and renewal of the medium, recombinant CPE cloned and purified as previously described ([Michl *et al*, 2001](#bib19){ref-type="other"}) was added to final concentrations ranging from 0.03 to 3.3 *μ*g ml^−1^. After incubation for 60 min to 24 h at 37°C, 5% CO~2~, floating cells were removed and stored, and attached cells were trypsinised and pooled with the floating cells. After staining with trypan blue, viability was determined by counting the number of trypan blue-positive cells and the total cell number.

RESULTS
=======

Gene expression profiles distinguish USPC from NEC and identify differentially expressed genes
----------------------------------------------------------------------------------------------

To minimise the risk of contamination of USPC RNA with that of normal cells or tumour cells with different histology (i.e., endometrioid or clear cells), as well as to reduce the complexity of gene expression data analysis, in this study we extracted RNA from short-term primary tumour cell cultures collected only from USPC with single-type differentiation (i.e., pure USPC). Short-term USPC and NEC cell cultures, minimising the risk of a selection bias inherent in any long-term *in vitro* growth, may provide an opportunity to study differential gene expression between highly enriched populations of normal and tumour-derived epithelial cells. Accordingly, comprehensive gene expression profiles of 10 primary USPC and five primary NEC cell lines were generated using high-density oligonucleotide arrays with 12 588 probe sets, which in total interrogated some 10 000 genes. Using unsupervised hierarchical cluster analysis with 7238 probe sets, we identified differences in gene expression between USPC and NEC, which readily distinguished the two groups of primary cultures. As shown in [Figure 1](#fig1){ref-type="fig"}, all 10 USPC were found to group together in the rightmost columns of the dendrogram. Similarly, in the leftmost columns, all five NEC were found to cluster tightly together. After filtering out most 'absent\' genes, the SAM and the nonparametric WRS test (*P*\<0.05) were performed to identify genes differentially expressed between USPC and NEC. A total of 2829 probe sets were found differentially expressed between USPC and NEC with *P*\<0.05 by WRS and with a median FDR of 0.35% and a 90th percentile FDR of 0.59% by SAM. Of the 2829 aforementioned probe sets, there were 529 probe sets showing \>5-fold change. As shown in [Table 2](#tbl2){ref-type="table"}, a group of 139 probe sets were found highly expressed in USPC and underexpressed in NEC. Included in this group of genes are *CDKN2A/p16/p14ARF* (101-fold), *L1CAM* (25-fold), *claudin-3* (eight-fold), and *claudin-4* (12-fold), *kallikrein 6* (*protease M*) (19-fold), *and kallikrein 10 (NES1)* (23-fold), *interleukin-6* (19-fold), *interleukin-18* (10-fold), and *plasminogen activator receptor* (*PLAUR*) (seven-fold) ([Table 2](#tbl2){ref-type="table"}). Importantly, *c-erbB2*, a gene recently found by our group to be highly differentially expressed in USPC when compared to ovarian serous papillary tumours ([Santin *et al*, 2004](#bib28){ref-type="other"}), was 14-fold more highly expressed in USPC than in NEC ([Table 2](#tbl2){ref-type="table"}). The second profile was represented by 390 genes that were highly expressed in NEC and underexpressed in USPC. [Table 3](#tbl3){ref-type="table"} depicts the genes showing \>10-fold change. Included in this group of genes are *transforming growth factor beta receptor III*, *platelet-derived growth factor receptor alpha*, *SEMACAP3*, *ras homolog gene family*, *member I* (*ARHI*), and *differentially downregulated in ovarian carcinoma 1* (*DOC1*).

Validation of the microarray data
---------------------------------

We used q-RT--PCR assays to validate the microarray data. Seven highly differentially expressed genes between USPC and NEC (i.e., *CDKN2A/p16, CDKN2A/p14ARF* (101-fold), *L1CAM* (25-fold), *claudin-3* (eight-fold), *claudin-4* (12-fold), *GRB-7* (19-fold), and *c-erbB2* (14-fold)) were selected for q-RT--PCR analysis. A comparison of the microarray and q-RT--PCR data for six of these genes is shown in [Figure 2](#fig2){ref-type="fig"}. Expression differences between USPC and NEC for *CDKN2A/p16* (*P*=0.002), *CDKN2A/p14ARF* (*P*=0.002), *claudin-3* (*P*=0.01), *claudin-4* (*P*=0.002), *GRB-7* (*P*=0.002) and *c-erbB2* (*P*=0.01) were readily apparent ([Table 2](#tbl2){ref-type="table"} and [Figure 2](#fig2){ref-type="fig"}). Moreover, for all seven genes tested, the q-RT--PCR data were highly correlated to the microarray data (*P*\<0.001) (*r*=0.81, 0.80, 0.75, 0,69, 0.82, 0.71 and 0.65, respectively), with all the samples (i.e., 10 USPC and five NEC) included in both the q-RT--PCR and microarray experiments. Thus, q-RT--PCR data suggest that most array probe sets are likely to accurately measure the levels of the intended transcript within a complex mixture of transcripts.

Claudin-4 expression by immunohistology on USPC and NEC tissue blocks
---------------------------------------------------------------------

To determine whether the high or low expression of the *claudin-4* gene detected by microarray and q-RT--PCR assays in primary USPC and NEC cell lines, respectively, is the result of a selection of a subpopulation of cancer cells present in the original tumour, or whether *in vitro* expansion conditions may have modified gene expression, we performed immunohistochemical analysis of claudin-4 protein expression on formalin-fixed tumour tissue from the uncultured primary surgical specimens from which the USPC cell lines were derived. As shown in [Table 4](#tbl4){ref-type="table"} and representatively in [Figure 3](#fig3){ref-type="fig"}, both cytoplasmic and membranous staining for claudin-4 protein expression was noted in the majority of USPC specimens (i.e., 90% score 3+ and 2+). In contrast, only low levels of membranous staining for claudin-4 protein was found in the NEC tissue samples tested by immunohistochemistry ([Table 4](#tbl4){ref-type="table"}, [Figure 3](#fig3){ref-type="fig"}, *P*=0.02 USPC *vs* NEC by Student *t*-test). To confirm and validate the immunohistochemical results in an independent series of USPC, formalin-fixed tumour tissue blocks from eight further surgical specimens (i.e., USPC 11--18, [Table 4](#tbl4){ref-type="table"}) similarly obtained from patients harbouring advanced stage disease were tested for claudin-4 expression. Again, heavy cytoplasmic and/or membranous staining for the claudin-4 receptor was found in the striking majority of the further USPC sample tested.

Effects of CPE on primary USPC and normal control cells
-------------------------------------------------------

The sensitivity of primary uterine serous tumour cultures to CPE-mediated cytolysis was tested along with an appropriate claudin-3- and claudin-4-expressing positive control (i.e., Vero cells, obtained from the American Type Culture Collection), and negative controls which do not express detectable levels of either claudin-3 or claudin-4. As shown in [Figure 4](#fig4){ref-type="fig"}, all primary USPC tested were found highly sensitive to CPE-mediated cytolysis. The cytotoxic effect was dose dependent and was positively correlated to the levels of either claudin-3 or claudin-4 expression as tested by RT--PCR in tumor samples. Importantly, although uterine serous tumours demonstrated different sensitivities to CPE exposure, no USPC was found viable after 24 h exposure to CPE at the concentration of 3.3 *μ*g ml^−1^. In contrast, all normal controls tested, including endometrial epithelium, fibroblasts and mononuclear cells lacking claudin-3 or claudin-4, were not affected by CPE ([Figure 4](#fig4){ref-type="fig"}).

DISCUSSION
==========

This report represents the first communication of an investigation involving the genome-wide examination of differences in gene expression between primary USPC and normal endometrial cells (NEC). In this study, we have used short-term primary USPC and NEC cultures (to minimise the risk of a selection bias inherent in any long-term *in vitro* growth) to study differential gene expression in highly enriched populations of epithelial tumour cells and normal cells. We found that hierarchical clustering of the samples and gene expression levels within the samples led to the unambiguous separation of USPC from NEC. We detected 529 genes differentially expressed between USPC and NEC, whose average change in expression level between the two groups was at least five-fold and which were found significant with both WRS test and SAM analysis. The known function of some of these genes may provide insights into the molecular pathogenesis and the highly aggressive biologic behaviour of uterine serous tumours, while others may prove to be useful diagnostic and therapeutic markers against this disease.

For example, the cyclin-dependent kinase inhibitor 2A (*CDKN2A*) gene was found to be the most highly differentially expressed gene in USPC with over 101-fold upregulation relative to NEC. Importantly, the *CDKN2A* gene is a putative oncosuppressor gene encoding two unrelated proteins, both cellular growth inhibitors, in different reading frames ([Quelle *et al*, 1995](#bib23){ref-type="other"}). One is p16, which regulates retinoblastoma protein (pRb)-dependent G1 arrest, and the second is p14ARF, which blocks MDM2-induced p53 degradation, resulting in an increase in p53 levels and consequent cell cycle arrest ([Quelle *et al*, 1995](#bib23){ref-type="other"}). Although loss of p53 function is considered critical for the molecular pathogenesis of USPC ([Moll *et al*, 1996](#bib20){ref-type="other"}), it is only recently that abnormality of the Rb pathway has been suggested to define a subgroup of aggressive endometrial carcinomas with poor prognosis ([Salvesen *et al*, 2000](#bib26){ref-type="other"}). Quantitative RT-PCR analysis of expression of both p16 and p14ARF in our USPC series found extremely high levels of both transcripts, suggesting that the marked overexpression of the *CDKN2A* gene may be attributable to a negative feedback loop due to the loss of function of both pRb and p53 proteins ([Moll *et al*, 1996](#bib20){ref-type="other"}; [Salvesen *et al*, 2000](#bib26){ref-type="other"}). Consistent with this view, an inverse relationship between the expression of p16 and p14ARF proteins and the presence of normal or functional Rb and p53 in human cancer cells has been previously demonstrated ([Khleif *et al*, 1996](#bib11){ref-type="other"}). Thus, our data suggest for the first time that *CDKN2A* gene overexpression may represent a consistent genetic anomaly of USPC secondary to an autoregulatory feedback loop due to disruption of both the p16-CDK4/cyclin D1-pRb pathway and the p14ARF-MDM2-p53 pathway.

Among the several potential therapeutic target gene products identified, genes encoding tight junction (TJ) proteins claudin-3 and claudin-4 were consistently found as two of the most highly upregulated genes in USPC, with over eight- and 12-fold upregulation, respectively, relative to NEC. To the best of our knowledge, claudin-3 and claudin-4 overexpression has not been previously linked to USPC. Although the exact function of claudin-3 and claudin-4 in USPC is still unclear, these proteins have recently been shown to represent the epithelial receptors for CPE ([Katahira *et al*, 1997](#bib10){ref-type="other"}), and to be the only family members of the transmembrane tissue-specific claudin proteins capable of mediating CPE binding and cytolysis. As CPE may trigger a multistep mechanism leading to efficient lysis of mammalian target cells overexpressing claudin-3 and claudin-4 by an increase in membrane permeability resulting in loss of osmotic equilibrium ([McClane 1996](#bib17){ref-type="other"}), CPE-mediated therapy might be a novel, potentially highly effective, strategy for the treatment of USPC refractory to chemotherapy as well as other human tumours overexpressing claudin-3 and/or claudin-4 ([Long *et al*, 2001](#bib13){ref-type="other"}; [Michl *et al*, 2001](#bib19){ref-type="other"}). Mammalian cells that do not express either claudin-3 and/or claudin-4 fail to bind CPE and are not susceptible to CPE cytotoxicity ([McClane 1996](#bib17){ref-type="other"}). Consistent with this view, all primary USPC evaluated, including those found to be resistant to chemotherapy *in vivo* (i.e., USPC-1 and USPC-2, data not shown), were found highly sensitive to CPE-mediated killing *in vitro*. This was in strong contrast with the lack of sensitivity of normal control cells to CPE-mediated cytolysis. Although USPC tumours demonstrated different sensitivity to CPE exposure, no cancer was found viable after 24 h exposure to CPE at a concentration of 3.3 *μ*g ml^−1^, a dose well tolerated by *in vivo* administration of CPE in murine animal models ([Wallace *et al*, 1999](#bib35){ref-type="other"}). More extensive studies will be necessary to evaluate the potential and feasibility of CPE therapy *in vivo* in human patients. Nevertheless, our results provide strong evidence to suggest that CPE-based therapy may have great potential in the treatment of USPC patients refractory to standard treatment modalities. Protein expression data obtained by immunohistochemistry with anti-claudin-4 antibody on an independent set of USPC blocks further support the proposal that claudins may represent therapeutic targets.

The organization of kallikreins, a gene family now consisting of 15 genes that encode for trypsin-like or chymotrypsin-like serine proteases, has been recently elucidated ([Diamandis and Yousef, 2002](#bib5){ref-type="other"}). Serine proteases have well-characterized roles in diverse cellular activities, including blood coagulation, wound healing, digestion, and immune responses, as well as tumour invasion and metastasis (reviewed in [Diamandis and Yousef, 2002](#bib5){ref-type="other"}). Secreted serine proteases such as prostate-specific antigen (PSA) and kallikrein 2 have already found important clinical application as prostate cancer biomarkers ([Diamandis and Yousef, 2002](#bib5){ref-type="other"}). Of interest, kallikrein 6 (also known as zyme/protease M/neurosin) and kallikrein-10 (NES1), two serine proteases recently shown to be present at high levels in the circulation of a subset of ovarian cancer patients ([Diamandis *et al*, 2003](#bib4){ref-type="other"}; [Luo *et al*, 2003](#bib15){ref-type="other"}), were both highly differentially expressed genes in USPC when compared to NEC. Kallikrein 6 and kallikrein 10 overexpression has been shown to correlate with intrinsic resistance to adjuvant chemotherapy and with a poor prognosis in ovarian cancer patients ([Diamandis *et al*, 2003](#bib4){ref-type="other"}; [Luo *et al*, 2003](#bib15){ref-type="other"}). These data are thus consistent with our results showing high expression of kallikrein 6 and kallikrein 10 in USPC, a variant of endometrial carcinoma characterised by an aggressive biologic behaviour and an inborn resistance to chemotherapy ([Nicklin and Copeland, 1996](#bib22){ref-type="other"}). In addition, these results further emphasise the view that kallikrein 6 and kallikrein 10 have the potential to become novel cancer markers for early diagnosis and/or monitoring of USPC, as well as possible immunotherapeutic targets of vaccination strategies against recurrent/refractory serous papillary gynecologic tumours ([Cannon *et al*, 2002](#bib3){ref-type="other"}).

*c-erbB2* gene was found to be one of the most highly differentially expressed gene in USPC with over 14-fold upregulation compared with NEC. Furthermore, the growth factor receptor-bound protein 7 (*GRB7*), a gene tightly linked to c-erbB2 and previously reported coamplified and coexpressed with this gene in several cancer types ([Janes *et al*, 1997](#bib8){ref-type="other"}), was also highly differentially expressed in USPC compared to NEC. These data confirm our recent discovery of a striking overexpression of the *c-erbB2* gene product HER2/neu on 80% of pure USPC ([Santin *et al*, 2002](#bib27){ref-type="other"}). Thus, HER2/neu overexpression may represent a distinctive molecular marker that, in addition to having the potential to facilitate differentiation of USPC from the histologically indistinguishable high-grade serious ovarian tumours ([Santin *et al*, 2004](#bib28){ref-type="other"}), may also provide insights into the disproportionately poor prognosis of USPC patients ([Lukes *et al*, 1994](#bib14){ref-type="other"}; [Santin *et al*, 2002](#bib27){ref-type="other"}, [2004](#bib28){ref-type="other"}). Previous studies have reported that HER2/neu overexpression in USPC patients may be associated with resistance to chemotherapeutic drugs and shorter survival ([Lukes *et al*, 1994](#bib14){ref-type="other"}). However, high overexpression of the *c-erbB2* gene on USPC provides support for the notion that trastuzumab (Herceptin, Genentech, San Francisco, CA, USA), a humanised anti-HER-2/Neu antibody that is showing great promise for treatment of metastatic breast cancer patients overexpressing HER-2/Neu protein ([Slamon *et al*, 2001](#bib29){ref-type="other"}), may be a novel, potentially highly effective therapy against USPC. Consistent with this view, high sensitivity of USPC to natural killer (NK) cell-mediated antibody-dependent cytotoxicity triggered by anti-HER-2/Neu-specific antibody *in vitro* ([Santin *et al*, 2002](#bib27){ref-type="other"}), as well as clinical responses *in vivo* ([Villella *et al*, 2003](#bib34){ref-type="other"}), have recently been reported with the use of Herceptin in USPC patients.

Several other highly ranked genes have been identified in our USPC gene expression profiling analysis, including membrane-associated protein 17 (MAP17), galanin, urokinase plasminogen activator receptor (UPAR), interleukin-6, forkhead box M1, interleukin-18, dickkopf homolog 1 (DKK1), coagulation factor II (thrombin) receptor-like 1, transforming growth factor, alpha, interleukin 8, topoisomerase (DNA) II alpha, hyaluronan-mediated motility receptor (RHAMM), and secretory leukocyte protease inhibitor (antileukoproteinase). For most of the genes found differentially expressed in our experiments, a correlation with USPC cancer development and progression has not been recognised before. DKK1, for example, has been recently reported by our group to play an important role in the development of osteolytic lesions in multiple myeloma ([Tian *et al*, 2003](#bib32){ref-type="other"}), but its possible role in USPC pathogenesis and/or progression has not been elucidated. For other genes such as UPAR, a glycosyl-phosphatidylinositol-anchored glycoprotein whose role in promoting tumour cell invasion and metastases has been well established in a number of experimental studies, a correlation with high expression in the USPC phenotype has been recently reported ([Memarzadeh *et al*, 2002](#bib18){ref-type="other"}).

A large number of downregulated (at least five-fold) genes in USPC *vs* NEC, such as *transforming growth factor beta receptor III*, *platelet-derived growth factor receptor alpha*, *SEMACAP3*, *ras homolog gene family member I* (*ARHI*), and *DOC1* ([Table 3](#tbl3){ref-type="table"}), have been identified in our analysis. Some of these genes encode for widely held tumor suppressor genes such as *SEMACAP3*, *ARHI*, and *DOC1* ([Liu and Ganesan, 2002](#bib12){ref-type="other"}), others for proteins important for tissue homeostasis or that have been previously implicated in apoptosis, proliferation, adhesion, or tissue maintenance. Owing to space limitations, we will not comment further upon the cluster of genes that showed downregulation of the transcripts in invasive tumours.

In conclusion, multiple USPC restricted markers have been identified through our analysis. Most of these genes have not been previously linked with this disease and thus represent novel findings. The identification of HER2/neu and CPE epithelial receptors among others as some of the most highly differentially expressed genes in USPC when compared to NEC suggest that therapeutic strategies targeting HER2/neu by monoclonal antibodies ([Villella *et al*, 2003](#bib34){ref-type="other"}) and claudin-3 and claudin-4 by local and/or systemic administration of CPE ([Long *et al*, 2001](#bib13){ref-type="other"}; [Michl *et al*, 2001](#bib19){ref-type="other"}) may represent novel potentially effective modalities for the treatment of patients harbouring this highly aggressive and chemotherapy-resistant variant of endometrial cancer. The future design and implementation of clinical trials at this regard will ultimately determine the validity of these approaches.

![Unsupervised hierarchical clustering of 15 primary uterine cell lines (i.e., 10 USPC and five NEC). The cluster is colour coded using *red* for upregulation, *green* for downregulation, and *black* for median expression. Agglomerative clustering of genes is illustrated with dendrograms.](92-6602480f1){#fig1}

![Quantitative RT--PCR and microarray expression analysis of *CDKN2A/p16*, *CDKN2A/p14ARF*, *claudin-3*, *claudin-4*, *GRB-7* and *c-erbB2* genes differentially expressed between USPC and NEC. Quantitative RT-PCR data were highly correlated to the microarray data (*P*\<0.001).](92-6602480f2){#fig2}

![Representative immunohistochemical staining for claudin-4 on two paraffin-embedded USPC specimens (**B**--**C**) and one NEC specimen (**A**). Normal endometrial cell 1 (upper panel) showed light membrane staining for claudin-4, while USPC 1 and USPC 3 showed heavy cytoplasmic and membranous staining for claudin-4 (middle and lower panel). Note the large difference in the size of USPC cells when compared to the control glandular epithelium of a menopausal women. Original magnification × 400.](92-6602480f3){#fig3}

![Representative dose-dependent CPE-mediated cytotoxicity of primary USPC compared to positive control Vero cells or negative controls (i.e., NEC, fibroblasts, and monocytes) after 24 h exposure to scalar doses of CPE. VERO, positive control cells. Uterine serous papillary carcinoma-1 to USPC-3 primary uterine serous tumors. NEC, normal endometrial cells. Fibroblasts, normal human fibroblasts. Monocytes, normal mononuclear cells.](92-6602480f4){#fig4}

###### 

Characteristics of the patients

  **Patient**    **Age**  **Race**         **Stage**
  ------------- --------- --------------- -----------
  USPC 1           65     White              IV B
  USPC 2           75     Afro-American      III C
  USPC 3           75     Afro-American      IV A
  USPC 4           59     White              IV A
  USPC 5           59     White              III C
  USPC 6           62     Afro-American      IV B
  USPC 7           63     Afro-American      III C
  USPC 8           61     Afro-American      III C
  USPC 9           78     White              III C
  USPC 10          64     Afro-American      IV A

###### 

Upregulated genes expressed at least five-fold higher in USPC compared with NEC

  **Probe set**   **Gene symbol**   **SAM**   ***P* of WRS**   **Ratio USPC/NEC**   **Title**
  --------------- ----------------- --------- ---------------- -------------------- -------------------------------------------------------------------------------------------------------------------
  1713_s\_at      **CDKN2A**^a^     10.592    0.0027           101.9077377          'Cyclin-dependent kinase inhibitor 2A (melanoma, p16)\'
  36288_at        KRTHB1            4.573     0.0027           77.3983986           'Keratin, hair, basic, 1\'
  33272_at        SAA1              3.778     0.0063           45.74937337          Serum amyloid A1
  41294_at        KRT7              7.173     0.0027           41.46788873          Keratin 7
  32154_at        TFAP2A            7.637     0.0027           32.47929396          Transcription factor AP-2 alpha
  31610_at        MAP17             3.621     0.0093           30.28302802          Membrane-associated protein 17
  408_at          ---               4.070     0.0063           30.14111158          ---
  32821_at        LCN2              5.126     0.0027           27.69975608          Lipocalin 2 (oncogene 24p3)
  35174_i\_at     EEF1A2            2.840     0.0278           26.80482891          Elongation factor 1 alpha 2
  38551_at        **L1CAM**         3.115     0.0196           25.60938089          'L1 cell adhesion molecule
  38249_at        VGLL1             5.274     0.0027           24.69495091          Vestigial like 1 (Drosophila)
  35879_at        GAL               5.594     0.0027           23.48953559          Galanin
  36838_at        KLK10             3.455     0.0136           23.17518549          Kallikrein 10
  38299_at        IL6               3.630     0.0041           19.05873079          'Interleukin 6 (interferon, beta 2)\'
  38051_at        MAL               4.878     0.0041           17.51555106          'mal, T-cell differentiation protein\'
  41469_at        PI3               2.854     0.0063           16.90464558          'Protease inhibitor 3, skin-derived (SKALP)\'
  40412_at        PTTG1             5.218     0.0027           16.61222352          Pituitary tumour-transforming 1
  1886_at         WNT7A             3.544     0.0196           16.11519778          'Wingless-type MMTV integration site family, member 7A\'
  33128_s\_at     CST6              4.222     0.0136           15.97856318          Cystatin E/M
  38414_at        CDC20             7.317     0.0027           15.64601435          CDC20 cell division cycle 20 homolog (*S. cerevisiae*)
  34012_at        KRTHA4            2.411     0.0278           15.37247475          'Keratin, hair, acidic, 4\'
  37554_at        KLK6              3.785     0.0093           15.23781352          'Kallikrein 6 (neurosin, zyme)\'
  1802_s\_at      **ERBB2**         2.566     0.0136           14.52012028          'v-erb-b2\'
  41060_at        CCNE1             6.092     0.0027           14.16647068          Cyclin E1
  36837_at        KIF2C             6.130     0.0027           14.1328483           Kinesin family member 2C
  34213_at        KIBRA             5.301     0.0027           13.27228177          KIBRA protein
  1651_at         UBE2C             5.554     0.0027           12.87617243          Ubiquitin-conjugating enzyme E2C
  35276_at        **CLDN4**         6.381     0.0027           12.74825421          Claudin 4
  36990_at        UCHL1             4.623     0.0027           12.30505908          Ubiquitin carboxyl-terminal esterase L1
  35977_at        DKK1              4.495     0.0041           12.25382636          Dickkopf homolog 1 (*Xenopus laevis*)
  36113_s\_at     TNNT1             4.072     0.0027           11.93824813          'Troponin T1, skeletal, slow\'
  2011_s\_at      BIK               3.451     0.0063           11.66959681          BCL2-interacting killer (apoptosis-inducing)
  543_g\_at       CRABP1            3.193     0.0093           11.55494382          Cellular retinoic acid binding protein 1
  34852_g\_at     STK6              6.225     0.0027           11.51812047          Serine/threonine kinase 6
  33483_at        NMU               4.094     0.0027           11.42057993          Neuromedin U
  39109_at        TPX2              6.162     0.0027           11.29208457          'TPX2, microtubule-associated protein homologue\'
  37018_at        HIST1H1C          2.270     0.0278           10.74270622          'Histone 1, H1c\'
  1165_at         IL18              3.221     0.0041           10.65596528          Interleukin 18 (interferon-gamma-inducing factor)
  36477_at        TNNI3             2.867     0.0136           10.61101382          'Troponin I, cardiac\'
  572_at          TTK               3.720     0.0093           9.723902052          TTK protein kinase
  31542_at        FLG               2.622     0.0196           9.600831601          Filaggrin
  35937_at        MICB              4.238     0.0093           9.460109582          MHC class I polypeptide-related sequence B
  36155_at        SPOCK2            2.278     0.0278           9.216570003          'Sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 2\'
  32186_at        SLC7A5            4.149     0.0063           9.121679665          'Solute carrier family 7 (cationic amino-acid transporter, *y*+ system), member 5\'
  35766_at        KRT18             5.933     0.0027           9.01220054           Keratin 18
  35822_at        BF                3.267     0.0063           8.952514469          'B-factor, properdin\'
  35714_at        PDXK              6.550     0.0027           8.898191704          'Pyridoxal (pyridoxine, vitamin B6) kinase\'
  1369_s\_at      ---               2.679     0.0196           8.773380878          ---
  40079_at        RAI3              4.516     0.0063           8.626843209          Retinoic acid induced 3
  37168_at        LAMP3             2.838     0.0136           8.616807346          Lysosomal-associated membrane protein 3
  39704_s\_at     HMGA1             5.322     0.0027           8.597894471          High-mobility group AT-hook 1
  1887_g\_at      WNT7A             3.003     0.0196           8.491813649          'Wingless-type MMTV integration site family, member 7A\'
  36929_at        LAMB3             5.770     0.0027           8.354149098          'Laminin, beta 3\'
  527_at          CENPA             6.126     0.0027           8.32992789           'Centromere protein A, 17 kDa\'
  41081_at        BUB1              4.883     0.0027           8.213759056          BUB1 budding uninhibited by benzimidazoles 1 homologue
  885_g\_at       ITGA3             4.447     0.0027           8.20660555           'Integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor)\'
  2021_s\_at      CCNE1             4.399     0.0041           8.199388463          Cyclin E1
  33904_at        **CLDN3**         3.296     0.0136           8.020010794          Claudin 3
  33730_at        RAI3              4.648     0.0041           7.923899439          Retinoic acid induced 3
  34736_at        CCNB1             5.078     0.0063           7.896644626          Cyclin B1
  757_at          ANXA2             3.514     0.0063           7.870466864          Annexin A2
  910_at          TK1               3.934     0.0093           7.869091533          'Thymidine kinase 1, soluble\'
  34851_at        STK6              4.491     0.0041           7.764803777          Serine/threonine kinase 6
  34703_f\_at     ---               2.275     0.0278           7.710260816          ---
  34715_at        FOXM1             5.318     0.0027           7.659023602          Forkhead box M1
  38971_r\_at     TNIP1             6.800     0.0027           7.595036872          TNFAIP3 interacting protein 1
  32263_at        CCNB2             4.246     0.0063           7.578513543          Cyclin B2
  1680_at         **GRB7**          4.013     0.0027           7.471384928          Growth factor receptor-bound protein 7
  38247_at        F2RL1             3.185     0.0093           7.432476326          Coagulation factor II (thrombin) receptor-like 1
  160025_at       TGFA              6.088     0.0027           7.355344272          'Transforming growth factor, alpha\'
  1945_at         CCNB1             5.298     0.0041           7.291039832          Cyclin B1
  31792_at        ANXA3             4.873     0.0041           7.266892828          Annexin A3
  182_at          ITPR3             5.432     0.0027           7.172450367          'Inositol 1,4,5-triphosphate receptor, type 3\'
  1117_at         CDA               2.937     0.0093           7.114518646          Cytidine deaminase
  902_at          EPHB2             5.186     0.0027           7.065363569          EphB2
  634_at          PRSS8             5.216     0.0041           7.001894703          'Protease, serine, 8 (prostasin)\'
  41169_at        PLAUR             3.982     0.0063           7.00139089           'Plasminogen activator, urokinase receptor\'
  33203_s\_at     FOXD1             3.464     0.0093           6.989749222          Forkhead box D1
  40095_at        CA2               4.285     0.0027           6.946396937          Carbonic anhydrase II
  38940_at        AD024             5.065     0.0041           6.928406028          AD024 protein
  34348_at        SPINT2            6.263     0.0027           6.877224695          'Serine protease inhibitor, Kunitz type, 2\'
  33933_at        WFDC2             3.344     0.0136           6.820073691          WAP four-disulphide core domain 2
  35281_at        LAMC2             3.347     0.0093           6.7580474            'Laminin, gamma 2\'
  349_g\_at       KIFC1             5.275     0.0041           6.700913018          Kinesin family member C1
  33218_at        ERBB2             2.710     0.0027           6.615105998          'v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)\'
  38881_i\_at     TRIM16            3.001     0.0196           6.506893575          Tripartite motif-containing 16
  1536_at         CDC6              4.666     0.0041           6.463305623          CDC6 cell division cycle 6 homolog (*S. cerevisiae*)
  38482_at        CLDN7             4.931     0.0041           6.409117877          Claudin 7
  40697_at        CCNA2             3.396     0.0093           6.40768505           Cyclin A2
  41688_at        TM4SF11           4.390     0.0027           6.366861533          Transmembrane 4 superfamily member 11 (plasmolipin)
  38158_at        ESPL1             6.007     0.0027           6.225688779          Extra spindle poles like 1 (*S. cerevisiae*)
  38474_at        CBS               3.380     0.0093           6.212078913          Cystathionine-beta-synthase
  36483_at        GALNT3            3.890     0.0041           6.181109111          UDP-*N*-acetyl-alpha-[D]{.smallcaps}-galactosamine:polypeptide *N*-acetylgalactosaminyltransferase 3 (GalNAc-T3)
  35372_r\_at     IL8               2.360     0.0278           6.133149591          Interleukin 8
  41585_at        KIAA0746          4.436     0.0027           6.092207586          KIAA0746 protein
  36832_at        B3GNT3            5.457     0.0027           5.941291793          'UDP-GlcNAc:betaGal beta-1,3-*N*-acetylglucosaminyltransferase 3\'
  1107_s\_at      G1P2              3.938     0.0063           5.923287019          'Interferon, alpha-inducible protein (clone IFI-15K)\'
  35207_at        SCNN1A            3.076     0.0136           5.920739634          'Sodium channel, nonvoltage-gated 1 alpha\'
  36863_at        HMMR              2.830     0.0196           5.905038013          Hyaluronan-mediated motility receptor (RHAMM)
  38631_at        TNFAIP2           4.924     0.0027           5.897745642          'Tumour necrosis factor, alpha-induced protein 2\'
  36813_at        TRIP13            5.666     0.0027           5.870351247          Thyroid hormone receptor interactor 13
  41048_at        PMAIP1            3.490     0.0062           5.853172336          Phorbol-12-myristate-13-acetate-induced protein 1
  2084_s\_at      ETV4              3.743     0.0093           5.798002338          'ets variant gene 4 (E1A enhancer binding protein, E1AF)\'
  33245_at        MAPK13            3.775     0.0136           5.766618762          Mitogen-activated protein kinase 13
  37347_at        CKS1B             5.543     0.0027           5.762817533          CDC28 protein kinase regulatory subunit 1B
  34282_at        NFE2L3            2.668     0.0136           5.734907375          Nuclear factor (erythroid-derived 2)-like 3
  330_s\_at       ---               4.026     0.0041           5.726752495          ---
  41732_at        na                6.920     0.0027           5.706487141          Similar to My016 protein
  1516_g\_at      ---               6.726     0.0027           5.63870137           ---
  904_s\_at       TOP2A             3.419     0.0063           5.634251452          Topoisomerase (DNA) II alpha 170 kDa
  36041_at        EXO1              4.971     0.0027           5.59235892           Exonuclease 1
  33143_s\_at     SLC16A3           4.007     0.0063           5.56591457           'Solute carrier family 16 (monocarboxylic acid transporters), member 3\'
  37228_at        PLK               4.501     0.0041           5.564532365          Polo-like kinase (Drosophila)
  1854_at         MYBL2             4.117     0.0063           5.54317592           v-myb myeloblastosis viral oncogene homolog (avian)-like 2
  40407_at        KPNA2             4.189     0.0041           5.51635645           'Karyopherin alpha 2 (RAG cohort 1, importin alpha 1)\'
  33282_at        LAD1              3.904     0.0063           5.509367036          Ladinin 1
  40145_at        TOP2A             3.307     0.0093           5.48127065           Topoisomerase (DNA) II alpha 170 kDa
  1100_at         IRAK1             5.530     0.0027           5.470162749          Interleukin-1 receptor-associated kinase 1
  37883_i\_at     AF038169          3.160     0.0027           5.460495655          Hypothetical protein AF038169
  37343_at        ITPR3             5.258     0.0027           5.449013729          'Inositol 1,4,5-triphosphate receptor, type 3\'
  31598_s\_at     GALE              4.647     0.0027           5.442955253          'Galactose-4-epimerase, UDP-\'
  889_at          ITGB8             2.744     0.0093           5.370592815          'Integrin, beta 8\'
  37558_at        IMP-3             3.123     0.0093           5.364127468          IGF-II mRNA-binding protein 3
  32715_at        VAMP8             5.686     0.0027           5.352873419          Vesicle-associated membrane protein 8 (endobrevin)
  36312_at        SERPINB8          3.611     0.0027           5.327343554          'Serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 8\'
  37210_at        INA               3.551     0.0063           5.307526088          'Internexin neuronal intermediate filament protein, alpha\'
  35699_at        BUB1B             3.665     0.0196           5.279075308          BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast)
  32787_at        ERBB3             2.658     0.0041           5.247404657          v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian)
  32275_at        SLPI              3.726     0.0041           5.221163981          Secretory leukocyte protease inhibitor (antileukoproteinase)
  893_at          E2-EPF            3.775     0.0063           5.196412396          Ubiquitin carrier protein
  41583_at        FEN1              5.481     0.0027           5.196005796          Flap structure-specific endonuclease 1
  41781_at        PPFIA1            4.113     0.0027           5.194931774          'Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1\'
  40726_at        KIF11             2.941     0.0093           5.1806793            Kinesin family member 11
  41400_at        TK1               4.246     0.0093           5.167172588          'Thymidine kinase 1, soluble\'
  41409_at        C1orf38           3.109     0.0063           5.100239097          Chromosome 1 open reading frame 38
  40425_at        EFNA1             2.738     0.0196           5.067718102          Ephrin-A1
  32081_at        CIT               6.162     0.0027           5.043567722          'Citron (rho-interacting, serine/threonine kinase 21)\'
  1108_s\_at      EPHA1             4.864     0.0027           5.040980858          EphA1
  33338_at        STAT1             3.275     0.0063           5.029498048          'Signal transducer and activator of transcription 1, 91 kDa\'

Genes selected for further analysis are identified with bold letters.

###### 

Upregulated genes expressed at least 10-fold higher in NEC compared with USPC

  **Probe set**   **Gene symbol**   **SAM**   ***P* of WRS**   **Ratio NEC/USPC**   **Title**
  --------------- ----------------- --------- ---------------- -------------------- -----------------------------------------------------------------------------------------------------------------------------
  774_g\_at       MYH11             17.611    0.0027           1014.968759          'Myosin, heavy polypeptide 11, smooth muscle\'
  773_at          MYH11             14.265    0.0027           968.0223497          'Myosin, heavy polypeptide 11, smooth muscle\'
  32582_at        MYH11             11.277    0.0027           212.2458648          'Myosin, heavy polypeptide 11, smooth muscle\'
  36681_at        APOD              11.714    0.0027           137.3140116          Apolipoprotein D
  1501_at         IGF1              8.321     0.0027           128.0651104          Insulin-like growth factor 1 (somatomedin C)
  39325_at        EBAF              8.177     0.0027           123.064609           'Endometrial bleeding associated factor)\'
  767_at          ---               12.707    0.0027           119.5409103          ---
  40398_s\_at     MEOX2             10.182    0.0027           114.9489897          Mesenchyme homeo box 2
  40776_at        DES               9.738     0.0027           109.416397           Desmin
  1197_at         ACTG2             5.861     0.0027           96.65715109          'Actin, gamma 2, smooth muscle, enteric\'
  36627_at        SPARCL1           7.724     0.0027           93.89302842          'SPARC-like 1 (mast9, hevin)\'
  37407_s\_at     MYH11             11.893    0.0027           88.70362054          'Myosin, heavy polypeptide 11, smooth muscle\'
  39673_i\_at     ECM2              8.459     0.0027           82.52353674          'Extracellular matrix protein 2, female organ and adipocyte specific\'
  39701_at        PEG3              7.645     0.0027           73.87997223          Paternally expressed gene 3
  39066_at        MFAP4             9.383     0.0027           68.84723295          Microfibrillar-associated protein 4
  38737_at        IGF1              6.341     0.0027           65.13666715          Insulin-like growth factor 1 (somatomedin C)
  35730_at        ADH1B             9.759     0.0027           64.94146631          'Alcohol dehydrogenase IB (class I), beta polypeptide\'
  41124_r\_at     ENPP2             7.007     0.0027           53.43118221          Ectonucleotide pyrophosphatase/phosphodiesterase 2 (autotaxin)
  36749_at        CPA3              9.096     0.0027           53.07347991          Carboxypeptidase A3 (mast cell)
  39616_at        PTGER3            10.188    0.0027           52.65326101          Prostaglandin E receptor 3 (subtype EP3)
  33440_at        TCF8              7.220     0.0027           49.54168001          Transcription factor 8
  32666_at        CXCL12            7.168     0.0027           49.2359637           Chemokine (C--X--C motif) ligand 12
  38734_at        PLN               9.182     0.0027           47.86730799          Phospholamban
  34203_at        CNN1              5.051     0.0027           47.0209722           'Calponin 1, basic, smooth muscle\'
  37576_at        PCP4              12.468    0.0027           45.45542357          Purkinje cell protein 4
  36834_at        MOXD1             9.736     0.0027           44.20917891          'Monooxygenase, DBH-like 1\'
  37247_at        TCF21             9.810     0.0027           42.40051895          Transcription factor 21
  37701_at        RGS2              7.408     0.0027           42.29038464          'Regulator of G-protein signalling 2, 24 kDa\'
  779_at          COL4A6            5.840     0.0027           41.96325597          'Collagen, type IV, alpha 6\'
  37394_at        C7                9.835     0.0027           40.72326307          Complement component 7
  36533_at        PTGIS             6.097     0.0027           39.10052985          Prostaglandin I2 (prostacyclin) synthase
  32689_s\_at     ---               6.178     0.0027           36.96897988          ---
  32905_s\_at     TPSB2             6.873     0.0027           36.85974711          Tryptase beta 2
  33240_at        SEMACAP3          4.814     0.0027           36.54583796          Likely ortholog of mouse semaF cytoplasmic domain associated protein 3
  1466_s\_at      FGF7              8.628     0.0027           35.60413415          Fibroblast growth factor 7
  32686_at        PTGER3            7.397     0.0027           35.31357002          Prostaglandin E receptor 3 (subtype EP3)
  39690_at        ALP               6.951     0.0027           33.76045029          Alpha-actinin-2-associated LIM protein
  38427_at        COL15A1           7.196     0.0027           32.85391153          'Collagen, type XV, alpha 1\'
  39939_at        COL4A6            6.846     0.0027           32.53815505          'Collagen, type IV, alpha 6\'
  37630_at        NRLN1             5.896     0.0027           31.03030255          Neuralin 1
  35717_at        ABCA8             7.587     0.0027           30.63819827          'ATP-binding cassette, subfamily A, member 8\'
  1709_g\_at      MAPK10            6.522     0.0027           30.54331363          Mitogen-activated protein kinase 10
  35679_s\_at     DPP6              5.899     0.0027           30.33959319          Dipeptidylpeptidase 6
  35740_at        EMILIN1           7.445     0.0027           29.45261895          Elastin microfibril interfacer 1
  41123_s\_at     ENPP2             6.597     0.0027           29.29614059          Ectonucleotide pyrophosphatase/phosphodiesterase 2 (autotaxin)
  755_at          ITPR1             8.211     0.0027           29.02124207          'Inositol 1,4,5-triphosphate receptor, type 1\'
  32847_at        MYLK              5.388     0.0027           28.22518538          'Myosin, light polypeptide kinase\'
  38001_at        CACNA1C           5.740     0.0027           27.31347302          'Calcium channel, alpha 1C subunit\'
  37279_at        GEM               9.925     0.0027           26.56613192          GTP-binding protein overexpressed in skeletal muscle
  36396_at        ---               5.901     0.0027           26.32457357          *Homo sapiens* mRNA; cDNA DKFZp586N2020 (from clone DKFZp586N2020)
  41137_at        PPP1R12B          12.043    0.0027           25.97089935          'Protein phosphatase 1, regulatory subunit 12B\'
  41405_at        SFRP4             10.077    0.0027           23.90433923          Secreted frizzled-related protein 4
  40775_at        ITM2A             6.152     0.0027           23.83083993          Integral membrane protein 2A
  38059_g\_at     DPT               6.508     0.0027           23.76376781          Dermatopontin
  41504_s\_at     MAF               5.331     0.0027           23.65323618          v-maf
  1596_g\_at      TEK               4.542     0.0027           23.37422615          'TEK tyrosine kinase, endothelial (venous malformations, multiple cutaneous and mucosal)\'
  914_g\_at       ERG               6.105     0.0027           22.63829292          v-ets erythroblastosis virus E26 oncogene like
  34283_at        ---               5.390     0.0041           22.19917455          '*Homo sapiens*, clone IMAGE:4791553, mRNA\'
  34388_at        COL14A1           9.452     0.0027           21.48165459          'Collagen, type XIV, alpha 1 (undulin)\'
  38994_at        SOCS2             6.600     0.0027           21.47663968          Suppressor of cytokine signaling 2
  36065_at        LDB2              5.790     0.0027           21.19321308          LIM domain binding 2
  40230_at        FRZB              5.962     0.0027           21.00467856          Frizzled-related protein
  33790_at        CCL15             9.017     0.0027           20.5510028           Chemokine (C--C motif) ligand 15
  33890_at        RGS5              7.347     0.0027           20.2203337           Regulator of G-protein signalling 5
  36513_at        MAGP2             4.385     0.0041           20.10734871          Microfibril-associated glycoprotein-2
  32526_at        JAM3              6.129     0.0027           19.89641568          Junctional adhesion molecule 3
  32687_s\_at     PTGER3            5.902     0.0027           19.7194642           Prostaglandin E receptor 3 (subtype EP3)
  35638_at        CBFA2T1           10.470    0.0027           19.57233853          'Core-binding factor, runt domain, alpha subunit 2; translocated to, 1; cyclin D-related\'
  34637_f\_at     ADH1A             6.291     0.0027           19.20847669          'Alcohol dehydrogenase 1A (class I)\'
  34675_at        SBLF              5.400     0.0027           19.04463285          Stoned B-like factor
  38351_at        ---               5.899     0.0026           18.69131208          *Homo sapiens* mRNA; cDNA DKFZp586L0120 (from clone DKFZp586L0120)
  1182_at         PLCL1             4.047     0.0027           18.50958764          Phospholipase C-like 1
  39681_at        ZNF145            6.266     0.0027           18.41823634          'Zinc-finger protein 145 (Kruppel-like, expressed in promyelocytic leukemia)\'
  1708_at         MAPK10            6.336     0.0027           18.31250756          Mitogen-activated protein kinase 10
  37765_at        LMOD1             7.586     0.0027           18.11624265          Leiomodin 1 (smooth muscle)
  1678_g\_at      IGFBP5            4.237     0.0041           17.88349387          Insulin-like growth factor binding protein 5
  35358_at        TENC1             9.243     0.0027           17.68277053          Tensin-like C1 domain-containing phosphatase
  33442_at        KIAA0367          6.830     0.0027           17.58195512          KIAA0367 protein
  37249_at        PDE8B             5.035     0.0027           17.25176904          Phosphodiesterase 8B
  33834_at        CXCL12            7.736     0.0027           17.10893345          Chemokine (C--X--C motif) ligand 12 (stromal cell-derived factor 1)
  35324_at        SLIT3             5.157     0.0027           17.08441711          Slit homolog 3 (*Drosophila*)
  37015_at        ALDH1A1           4.941     0.0027           16.83181709          'Aldehyde dehydrogenase 1 family, member A1\'
  39266_at        ---               6.237     0.0027           16.80733058          *Homo sapiens* clone 24405 mRNA sequence
  33462_at        GPR105            4.907     0.0027           16.49634139          G protein-coupled receptor 105
  32488_at        COL3A1            3.928     0.0027           16.44993439          'Collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, autosomal dominant)\'
  483_g\_at       CDH13             3.755     0.0027           16.43857351          'Cadherin 13, H-cadherin (heart)\'
  38026_at        FBLN1             5.350     0.0027           16.06497318          Fibulin 1
  1909_at         BCL2              7.356     0.0027           16.01160367          B-cell CLL/lymphoma 2
  36245_at        HTR2B             4.698     0.0027           15.77119379          5-Hydroxytryptamine (serotonin) receptor 2B
  32057_at        LRRC17            5.470     0.0027           15.6891271           Leucine-rich repeat containing 17
  39544_at        DMN               5.361     0.0027           15.66465434          Desmuslin
  37112_at        C6orf32           4.720     0.0027           15.65975413          Chromosome 6 open reading frame 32
  36733_at        FLJ32389          4.442     0.0027           15.64273348          Hypothetical protein FLJ32389
  1319_at         DDR2              5.400     0.0027           15.5817123           'Discoidin domain receptor family, member 2\'
  38057_at        DPT               8.479     0.0027           15.51358362          Dermatopontin
  40358_at        GLI3              6.650     0.0027           15.11249492          GLI-Kruppel family member GLI3 (Greig cephalopolysyndactyly syndrome)
  38627_at        HLF               4.947     0.0027           14.89249894          Hepatic leukemia factor
  1731_at         PDGFRA            7.050     0.0027           14.84422948          'Platelet-derived growth factor receptor, alpha polypeptide\'
  31897_at        DOC1              4.664     0.0027           14.80084961          Downregulated in ovarian cancer 1
  2073_s\_at      CDH13             5.076     0.0027           14.79118507          'Cadherin 13, H-cadherin (heart)\'
  38577_at        ---               7.283     0.0027           14.78670234          'Clone DT1P1B6 mRNA, CAG repeat region\'
  38004_at        CSPG4             6.072     0.0027           14.40637488          Chondroitin sulphate proteoglycan 4
  32109_at        FXYD1             7.333     0.0027           14.33463902          Phospholemman
  34853_at        FLRT2             9.834     0.0027           14.33080432          Fibronectin leucine-rich transmembrane protein 2
  38298_at        KCNMB1            7.046     0.0027           14.25816751          'Potassium large-conductance calcium-activated channel, subfamily M, beta member 1\'
  41245_at        GDF10             6.643     0.0027           14.21467179          Growth differentiation factor 10
  38322_at        GAGEC1            6.215     0.0027           14.10508119          'G antigen, family C, 1\'
  1198_at         EDNRB             4.899     0.0027           14.08196951          Endothelin receptor type B
  41505_r\_at     MAF               4.528     0.0027           14.0059518           v-maf
  36976_at        CDH11             3.692     0.0027           14.00329993          'Cadherin 11, type 2, OB-cadherin (osteoblast)\'
  32688_at        PTGER3            4.998     0.0027           13.68791213          Prostaglandin E receptor 3 (subtype EP3)
  1575_at         ABCB1             6.210     0.0027           13.64196645          'ATP-binding cassette, subfamily B\'
  32778_at        ITPR1             4.914     0.0027           13.60359986          'Inositol 1,4,5-triphosphate receptor, type 1\'
  40737_at        KCNMA1            5.642     0.0027           13.60011778          'potassium large-conductance calcium-activated channel, subfamily M, alpha member 1\'
  36569_at        TNA               11.512    0.0027           13.14186685          Tetranectin (plasminogen-binding protein)
  1897_at         TGFBR3            4.922     0.0041           12.99722509          'Transforming growth factor, beta receptor III (betaglycan, 300 kDa)\'
  2087_s\_at      CDH11             4.345     0.0027           12.96131894          'Cadherin 11, type 2, OB-cadherin (osteoblast)\'
  34820_at        PTN               4.413     0.0041           12.94626537          'Pleiotrophin (heparin binding growth factor 8, neurite growth-promoting factor 1)\'
  743_at          NAP1L3            7.859     0.0027           12.91061134          Nucleosome assembly protein 1-like 3
  1507_s\_at      EDNRA             4.319     0.0041           12.88466839          Endothelin receptor type A
  38995_at        CLDN5             12.156    0.0027           12.86636376          Claudin 5 (transmembrane protein deleted in velocardiofacial syndrome)
  1147_at         ---               7.084     0.0027           12.69931721          ---
  1954_at         KDR               6.077     0.0027           12.6174344           Kinase insert domain receptor (a type III receptor tyrosine kinase)
  38786_at        ---               5.676     0.0027           12.61170471          *Homo sapiens* mRNA full-length insert cDNA clone EUROIMAGE 248114
  40757_at        GZMA              4.575     0.0041           12.56281091          'Granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3)\'
  36695_at        na                5.776     0.0027           12.53905775          Similar to hypothetical protein 6720478C22
  32052_at        HBB               5.107     0.0063           12.52262761          'Haemoglobin, beta\'
  37446_at        GASP              8.227     0.0027           12.39360585          G protein-coupled receptor-associated protein
  38038_at        LUM               4.462     0.0027           12.34757673          Lumican
  32889_at        RPIB9             6.337     0.0027           12.34540513          Rap2-binding protein 9
  35234_at        RECK              4.476     0.0027           12.33793353          Reversion-inducing-cysteine-rich protein
  661_at          GAS1              4.648     0.0027           12.32556384          Growth arrest-specific 1
  41195_at        LPP               6.292     0.0027           12.26636801          LIM domain containing preferred translocation partner in lipoma
  32664_at        RNASE4            6.395     0.0027           11.89680804          'Ribonuclease, RNase A family, 4\'
  39038_at        FBLN5             4.325     0.0027           11.89440528          Fibulin 5
  40693_at        KCNB1             4.952     0.0041           11.84773944          'Potassium voltage-gated channel, Shab-related subfamily, member 1\'
  38052_at        F13A1             5.346     0.0027           11.69181717          'Coagulation factor XIII, A1 polypeptide\'
  35220_at        ENPEP             4.200     0.0027           11.66308093          Glutamyl aminopeptidase (aminopeptidase A)
  37512_at        RODH              5.112     0.0027           11.65031202          3-Hydroxysteroid epimerase
  103_at          THBS4             5.114     0.0027           11.6063075           Thrombospondin 4
  36156_at        AQP1              6.927     0.0027           11.6016663           'Aquaporin 1\'
  39593_at        FGL2              5.176     0.0027           11.38223584          Fibrinogen-like 2
  33248_at        HOXA11            6.555     0.0027           11.34828098          Homeo box A11
  41420_at        IGFBP5            4.166     0.0041           11.32365037          Insulin-like growth factor binding protein 5
  35644_at        HEPH              6.666     0.0027           11.26324425          Hephaestin
  39646_at        CACNB2            4.719     0.0027           11.25017414          'Calcium channel, voltage-dependent, beta 2 subunit\'
  35333_r\_at     DVS27             4.403     0.0027           11.23759398          DVS27-related protein
  33182_at        ---               4.990     0.0027           11.20258783          *Homo sapiens* mRNA full-length insert cDNA clone EUROIMAGE 1630957
  34303_at        FLJ90798          4.909     0.0027           11.10458088          Hypothetical protein FLJ90798
  33756_at        AOC3              5.186     0.0027           11.09776026          'Amine oxidase, copper containing 3 (vascular adhesion protein 1)\'
  37710_at        MEF2C             7.485     0.0027           11.03832245          'MADS box transcription enhancer factor 2, polypeptide C (myocyte enhancer factor 2C)\'
  35680_r\_at     DPP6              3.783     0.0027           10.88151987          Dipeptidylpeptidase 6
  40126_at        ---               4.620     0.0027           10.87424764          ---
  31831_at        SMTN              5.712     0.0027           10.84917408          Smoothelin
  234_s\_at       PTN               5.660     0.0041           10.803161            'Pleiotrophin (heparin binding growth factor 8, neurite growth-promoting factor 1)\'
  36939_at        GPM6A             4.981     0.0027           10.76644676          Glycoprotein M6A
  41158_at        PLP1              4.879     0.0027           10.76462278          'Proteolipid protein 1 (Pelizaeus-Merzbacher disease, spastic paraplegia 2, uncomplicated)\'
  41839_at        GAS1              4.401     0.0027           10.75375673          Growth arrest-specific 1
  1186_at         GDF10             4.165     0.0063           10.74677086          Growth differentiation factor 10
  35404_at        TACR2             4.416     0.0063           10.67366905          Tachykinin receptor 2
  160023_at       WNT2              5.424     0.0027           10.67077677          Wingless-type MMTV integration site family member 2
  34561_at        MS4A2             6.380     0.0027           10.6336763           'Membrane-spanning 4-domains, subfamily A, member 2 (Fc fragment of IgE, high affinity I, receptor for; beta polypeptide)\'
  36280_at        GZMK              4.739     0.0027           10.5607572           'Granzyme K\'
  35668_at        RAMP1             3.430     0.0027           10.4886967           Receptor (calcitonin) activity modifying protein 1
  32521_at        SFRP1             4.488     0.0027           10.43051698          Secreted frizzled-related protein 1
  1975_s\_at      IGF1              7.381     0.0027           10.34307322          Insulin-like growth factor 1 (somatomedin C)
  37671_at        LAMA4             5.094     0.0027           10.34084543          'Laminin, alpha 4\'
  40013_at        CLIC2             5.388     0.0027           10.2736905           Chloride intracellular channel 2
  32782_r\_at     BPAG1             4.597     0.0027           10.2197061           'Bullous pemphigoid antigen 1, 230/240 kDa\'
  36918_at        GUCY1A3           4.344     0.0027           10.18606373          'Guanylate cyclase 1, soluble, alpha 3\'
  32239_at        MATN2             6.197     0.0027           10.14895891          Matrilin 2
  36503_at        CCL21             6.812     0.0027           10.09354903          Chemokine (C--C motif) ligand 21
  38508_s\_at     TNXB              8.826     0.0027           10.0794719           Tenascin XB
  35146_at        TGFB1I1           5.562     0.0027           10.0680837           Transforming growth factor beta 1
  38653_at        PMP22             6.085     0.0027           10.04665889          Peripheral myelin protein 22
  342_at          ENPP1             5.008     0.0041           10.0434301           Ectonucleotide pyrophosphatase/phosphodiesterase
  32826_at        ENTPD1            6.423     0.0027           10.01186286          Ectonucleoside triphosphate diphosphohydrolase 1
  40318_at        DNCI1             3.348     0.0063           10.00454416          'Dynein, cytoplasmic, intermediate polypeptide 1\'

###### 

Claudin-4 staining

  **Patient**    **Claudin-4 positivity**
  ------------- --------------------------
  NEC 1                     1+
  NEC 2                     1+
  NEC 3                     1+
  NEC 4                     1+
  NEC 5                     1+
  USPC 1                    3+
  USPC 2                    3+
  USPC 3                    3+
  USPC 4                    2+
  USPC 5                    3+
  USPC 6                    2+
  USPC 7                    3+
  USPC 8                    1+
  USPC 9                    3+
  USPC 10                   3+
  USPC 11                   3+
  USPC 12                   3+
  USPC 13                   1+
  USPC 14                   2+
  USPC 15                   3+
  USPC 16                   2+
  USPC 17                   3+
  USPC 18                   2+
